Peptide Initiative

Peptides · Peptide comparison

LL-37 vs Polymyxin B

Human cathelicidin-derived antimicrobial peptide (37 amino acids) that disrupts bacterial membranes at MIC 0.62 μM against S. aureus, neutralizes endotoxin (LPS) to prevent septic shock, and has reached Phase II clinical trials as Ropocamptide for wound healing — achieving 6-fold accelerated healing at 0.5 mg/mL in venous leg ulcers

Cyclic lipopeptide antibiotic from Paenibacillus polymyxa containing 10 amino acids with 6 diaminobutyric acid residues and a fatty acid tail — FDA-approved since 1964 as a last-resort treatment for multidrug-resistant Gram-negative infections including Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae, targeting lipid A of bacterial lipopolysaccharide with rapid bactericidal membrane disruption

  • Immune
  • Immune

At a glance

Quick comparison

Dose rangeLL-371.6–1.6 mg/mLPolymyxin B1.25–1.5 mg/kg
FrequencyLL-37Once dailyPolymyxin BMultiple times daily
AdministrationLL-37Topical application (wound healing)Polymyxin BIntravenous infusion (on the FDA label)
Cycle lengthLL-3712+ weeksPolymyxin B7-14 days, infection-dependent — no source sets a fixed course
Onset speedLL-37Moderate (1-2 weeks)Polymyxin BRapid (hours to days)
Evidence levelLL-37Moderate human trials (Phase 1-2)Polymyxin BStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Wound Healing

LL-3794%
Polymyxin BNo recorded rating

Fighting Infections

LL-3791%
Polymyxin BNo recorded rating

Immune Boost

LL-3787%
Polymyxin BNo recorded rating

Fighting Resistant Infections

LL-37No recorded rating
Polymyxin B97%

Stopping Bacterial Toxins

LL-37No recorded rating
Polymyxin B88%

Wound Protection

LL-37No recorded rating
Polymyxin B82%

Technical data

Compound specifications

LL-37

Molecular formula
C205H340N60O53
Molecular weight
4,493.26 Da
Half-life
Short systemic half-life (minutes) due to protease susceptibility; local tissue persistence at wound sites is longer due to binding to extracellular matrix components and lipid membranes
Bioavailability
Topical application achieves high local wound-bed concentrations; systemic bioavailability limited by rapid proteolytic degradation and serum protein binding; not intended for oral delivery
CAS number
154947-66-7

Polymyxin B

Molecular formula
C₅₆H₉₈N₁₆O₁₃ (polymyxin B₁ free base)
Molecular weight
1,203.5 g/mol (free base); ~1,385 g/mol (sulfate salt)
Half-life
Terminal half-life: 9-11.5 hours in patients with normal renal function; does not require renal dose adjustment (unlike colistimethate); achieves steady-state within 1-2 days with loading dose
Bioavailability
IV: 100% (direct administration); oral: negligible (not absorbed from GI tract — used topically in the gut for selective decontamination); inhaled: local pulmonary concentrations achieved with systemic absorption variable; topical: minimal systemic absorption
CAS number
1405-20-5 (polymyxin B sulfate)

Protocols

Dosing compared

LL-37

Topical

  • 0.5 mg/mL gelTwice weekly · 4 weeksLowest dose in the LL-37 (ropocamptide) Phase I/IIa venous leg-ulcer trial and the most effective: ~6-fold faster healing and ~68% ulcer-area reduction vs placebo, applied to the wound twice weekly [4].
  • 1.6 mg/mL gelTwice weekly · 4 weeksMid dose in the same trial; ~3-fold improvement and ~50% area reduction vs placebo. The highest tested concentration (3.2 mg/mL) showed no benefit over placebo, so dose escalation above this is not supported [4].

Polymyxin B

Intravenous

  • Loading dose 2.0-2.5 mg/kg (20,000-25,000 units/kg)Once on day 1 · Day 1 loading, then maintenanceThe consensus loading dose for serious multidrug-resistant Gram-negative infection, by total body weight, infused over 1 hour [7]. It is not on the FDA label, which predates this guidance [6]. 1 mg of polymyxin B is 10,000 units — a dose quoted without saying which convention it uses cannot be interpreted [7].
  • 1.25-1.5 mg/kg (12,500-15,000 units/kg) per doseEvery 12 hours · 7-14 days, infection-dependentConsensus maintenance dosing, infused over 1 hour [7]. That works out to 2.5-3 mg/kg/day, or 25,000-30,000 units/kg/day — ABOVE the FDA label's stated maximum of 25,000 units/kg/day [6], which is one of the outdated-product-information problems the consensus panel was convened to resolve [7]. Unlike colistin, polymyxin B is not dose-reduced for renal impairment or dialysis [7]; the FDA label, written before that was understood, does instruct reduction in renal impairment [6]. This is a hospital drug given by clinicians who know which convention they are using.

Intramuscular

  • 25,000-30,000 units/kg/day divided every 4-6 hoursEvery 4-6 hours · Infection-dependentFDA label intramuscular dosing; not generally recommended due to injection-site pain. [6]

Intrathecal

  • 50,000 units once daily for 3-4 days, then 50,000 units every other dayDaily then every other day · At least 2 weeks after CSF cultures turn negativeFDA label intrathecal regimen for meningitis (adults and children >2 yr); typically given with concomitant IV polymyxin. Children <2 yr: 20,000 units/day for 3-4 days. [6]

Topical

  • 10,000-25,000 units/mL solution, 1-3 dropsHourly at first, lengthening the interval as the response allows · Until infection resolvesTopical and subconjunctival use for eye infections caused by susceptible Pseudomonas aeruginosa is on the FDA label [6]. The concentration is 0.1-0.25%, which is the same thing as 10,000-25,000 units per mL — written here in units because that is how the rest of this drug's dosing is expressed.

Applications

Best suited for

LL-37

Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers
LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [4].
Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)
LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3][5].
Anti-biofilm strategies for chronic wound infections and medical device-associated infections
LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
Boosting innate immune defense in immunocompromised or aging individuals
LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [2].

Polymyxin B

Treatment of life-threatening multidrug-resistant Gram-negative infections when carbapenems and other agents have failed
Polymyxin B is particularly well-suited for individuals focused on treatment of life-threatening multidrug-resistant gram-negative infections when carbapenems and other agents have failed. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Salvage therapy for carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections and pneumonia
Polymyxin B is particularly well-suited for individuals focused on salvage therapy for carbapenem-resistant acinetobacter baumannii (crab) bloodstream infections and pneumonia. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Intrathecal/intraventricular treatment of MDR Gram-negative meningitis and ventriculitis
Polymyxin B is particularly well-suited for individuals focused on intrathecal/intraventricular treatment of mdr gram-negative meningitis and ventriculitis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Inhaled therapy for MDR Gram-negative ventilator-associated pneumonia (VAP) as adjunct to systemic therapy
Polymyxin B is particularly well-suited for individuals focused on inhaled therapy for mdr gram-negative ventilator-associated pneumonia (vap) as adjunct to systemic therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

LL-37

Common

  • Local site irritation
  • Transient stinging or burning
  • Mild perilesional erythema
  • Increased wound exudate

Uncommon

  • Allergic contact reaction

Serious

  • Hemolytic activity at systemic concentrations

Polymyxin B

Common

  • Nephrotoxicity
  • Infusion-related histamine release
  • Neurotoxicity
  • Skin hyperpigmentation

Uncommon

  • Neuromuscular blockade

Serious

  • Acute kidney injury requiring dialysis

Research status

Safety & evidence

LL-37

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, [2] conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications.

Contraindications

  • Known hypersensitivity to cathelicidin peptides or formulation components
  • Active hemolytic conditions — LL-37 demonstrates concentration-dependent hemolytic activity
  • Pregnancy and breastfeeding — insufficient reproductive safety data from clinical trials
  • Severe renal impairment — peptide clearance may be altered

Polymyxin B

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved. Indicated for acute infections caused by susceptible Pseudomonas aeruginosa (urinary tract, meninges, bloodstream), and for serious infections caused by H. influenzae, E. coli, Aerobacter aerogenes and Klebsiella pneumoniae when less toxic drugs are ineffective or contraindicated. Carries a BOXED WARNING. Meningeal infections must be treated by the intrathecal route only.
Safety overview
Polymyxin B carries a BOXED WARNING, and it is the most important thing on this page [6]. When given intramuscularly or intrathecally it is to be given only to hospitalised patients under constant physician supervision. Renal function must be determined before use and dosage reduced in renal damage; nephrotoxicity shows as albuminuria, cellular casts and azotemia, and falling urine output with a rising BUN is an instruction to stop the drug. Neurotoxic reactions present as irritability, weakness, drowsiness, ataxia, perioral paraesthesia, numbness of the extremities and blurred vision, usually with the high serum levels seen in renal impairment. Most seriously, the label states the neurotoxicity CAN RESULT IN RESPIRATORY PARALYSIS FROM NEUROMUSCULAR BLOCKADE, especially when given soon after anaesthesia or muscle relaxants. The boxed warning names the drugs to avoid concurrently or sequentially: bacitracin, streptomycin, neomycin, kanamycin, gentamicin, tobramycin, amikacin, cephaloridine, paromomycin, viomycin and colistin. Safety in human pregnancy has not been established. Beyond the box, the label reports drug fever, urticarial rash, severe pain at intramuscular injection sites, thrombophlebitis at intravenous sites, and Clostridioides difficile associated diarrhoea ranging from mild to fatal colitis, which can begin more than two months after the antibiotic was given [6].

Contraindications

  • Prior hypersensitivity reaction to polymyxins — the FDA label's only stated contraindication [6]
  • Concurrent or sequential use of other neurotoxic or nephrotoxic drugs, which the boxed warning names: bacitracin, streptomycin, neomycin, kanamycin, gentamicin, tobramycin, amikacin, cephaloridine, paromomycin, viomycin and colistin [6]
  • Soon after anaesthesia or muscle relaxants — the boxed warning flags respiratory paralysis from neuromuscular blockade [6]
  • Pregnancy — the boxed warning states safety in human pregnancy has not been established [6]
  • Myasthenia gravis — neuromuscular blockade is the mechanism behind the label's respiratory-paralysis warning

Decision guide

Which is right for you?

LL-37

Choose LL-37 if…

  • Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers
  • Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)
  • Anti-biofilm strategies for chronic wound infections and medical device-associated infections
  • Boosting innate immune defense in immunocompromised or aging individuals

Polymyxin B

Choose Polymyxin B if…

  • Treatment of life-threatening multidrug-resistant Gram-negative infections when carbapenems and other agents have failed
  • Salvage therapy for carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections and pneumonia
  • Intrathecal/intraventricular treatment of MDR Gram-negative meningitis and ventriculitis
  • Inhaled therapy for MDR Gram-negative ventilator-associated pneumonia (VAP) as adjunct to systemic therapy